Inpatient prescribing patterns of long-acting injectables and their oral or short-acting injectable equivalent formulations
Conclusions: Compared with their oral or SAI formulations, LAIs were underutilized from 2010 to 2016. Among SGA LAIs, the prescribing patterns of paliperidone palmitate and risperidone changed significantly. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - May 22, 2023 Category: Drugs & Pharmacology Source Type: research
Feasibility study to evaluate capabilities for conducting psychiatric clinical research within the Rwandan mental healthcare system
Conclusions
This work was designed to strengthen global research in schizophrenia by building the capacity of researchers to prepare and conduct pharmaceutical trials in resource-limited settings. Although the study was ended early, modifications motivated by the results will facilitate the successful design and completion of more comprehensive studies, including an ongoing, follow-up interventional trial of PP1M/PP3M in a larger population of patients in Rwanda.
Trial registration number
NCT03713658 (Source: BMJ Open)
Source: BMJ Open - April 18, 2023 Category: General Medicine Authors: Alphs, L., Turkoz, I., Smith-Swintosky, V., Keenan, A., Abraham, E., Schotte, A., Hooker, E., Damascene Iyamuremye, J., Kayiteshonga, Y., Bizoza, R., Mancevski, B. Tags: Open access, Mental health Source Type: research
Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study
(Source: Neuropsychiatric Disease and Treatment)
Source: Neuropsychiatric Disease and Treatment - April 13, 2023 Category: Psychiatry Tags: Neuropsychiatric Disease and Treatment Source Type: research
Prescription of Long-Acting Injectable Antipsychotic Medications Among Outpatient Mental Health Care Service Providers
CONCLUSIONS: Prescription of LAIAPs is limited at outpatient mental health care service providers in the United States. Expansion of these services and diversification of delivery models are needed to improve LAIAP prescriptions, which are associated with improved patient outcomes across a broad range of measures.PMID:37042107 | DOI:10.1176/appi.ps.20220586 (Source: Psychiatric Services)
Source: Psychiatric Services - April 12, 2023 Category: Psychiatry Authors: Samuel R Bunting Kristen Chalmers Daniel Yohanna Royce Lee Source Type: research
Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database
DiscussionOur analysis indicates that the tolerability and safety profiles of PP are in line with what is known for the other SGA-LAIs. However, differences regarding endocrine system ADRs have been noticed. The results presented in this work do not discourage the prescription of SGA-LAI formulations but aim to enhance their safety. (Source: Frontiers in Psychiatry)
Source: Frontiers in Psychiatry - April 6, 2023 Category: Psychiatry Source Type: research
Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
(Source: Neuropsychiatric Disease and Treatment)
Source: Neuropsychiatric Disease and Treatment - April 5, 2023 Category: Psychiatry Tags: Neuropsychiatric Disease and Treatment Source Type: research
Case report: Successful administration of cariprazine in a young, severely ill patient with recurrent relapses of schizophrenia and persistent negative symptoms
The present case report describes a young man diagnosed with schizophrenia and presents a “revolving door” (RD) phenomenon. He was hospitalized in an acute psychiatric clinic three times in 1 year. After each hospitalization, he was discharged with incompletely reduced psychotic symptoms, persistent negative symptoms, low functioning, lack of insight, and adherence. He had an insufficient response to maximally tolerated doses of antipsychotic monotherapy with haloperidol and risperidone. Moreover, his treatment was complicated due to the low accessibility of long-acting injectable atypical antipsychotics (LAI) in the...
Source: Frontiers in Psychiatry - March 9, 2023 Category: Psychiatry Source Type: research
Paliperidone Palmitate: A Breakthrough Treatment for Schizophrenia? A Review on Patient Adherence Levels, Healthcare Resource Utilization and Costs
(Source: Neuropsychiatric Disease and Treatment)
Source: Neuropsychiatric Disease and Treatment - March 7, 2023 Category: Psychiatry Tags: Neuropsychiatric Disease and Treatment Source Type: research
IJERPH, Vol. 20, Pages 3403: Effectiveness of Paliperidone Palmitate in Reducing Acute Psychiatric Service Use for Patients Suffering from Psychosis & mdash;A Retrospective Mirror-Image Study
IJERPH, Vol. 20, Pages 3403: Effectiveness of Paliperidone Palmitate in Reducing Acute Psychiatric Service Use for Patients Suffering from Psychosis—A Retrospective Mirror-Image Study
International Journal of Environmental Research and Public Health doi: 10.3390/ijerph20043403
Authors:
Chun Ting Chan
Swapna Verma
Mythily Subramaniam
Edimansyah Abdin
Jenny Tay
Poor adherence to antipsychotic treatment is a leading cause of relapse for patients suffering from psychotic disorders and the use of long-acting injectable antipsychotics (LAI) may lead to improved clinical outcomes. This was a 1-year mirro...
Source: International Journal of Environmental Research and Public Health - February 15, 2023 Category: Environmental Health Authors: Chun Ting Chan Swapna Verma Mythily Subramaniam Edimansyah Abdin Jenny Tay Tags: Article Source Type: research
What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review
CONCLUSIONS: There are few studies assessing the use of LAIAs in adolescents with SSD. Overall, these treatments have suggested good effectiveness and acceptable safety and tolerability. However, we found no studies examining their use in children aged < 12 years. The problems and benefits linked to this type of antipsychotic formulation in the child and adolescent population require further study, ideally with prospective, controlled designs.PMID:36662369 | DOI:10.1007/s40272-023-00558-x (Source: Paediatric Drugs)
Source: Paediatric Drugs - January 20, 2023 Category: Pediatrics Authors: Inmaculada Baeza Adriana Fortea Daniel Ilzarbe Gisela Sugranyes Source Type: research
What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review
CONCLUSIONS: There are few studies assessing the use of LAIAs in adolescents with SSD. Overall, these treatments have suggested good effectiveness and acceptable safety and tolerability. However, we found no studies examining their use in children aged < 12 years. The problems and benefits linked to this type of antipsychotic formulation in the child and adolescent population require further study, ideally with prospective, controlled designs.PMID:36662369 | DOI:10.1007/s40272-023-00558-x (Source: Paediatric Drugs)
Source: Paediatric Drugs - January 20, 2023 Category: Pediatrics Authors: Inmaculada Baeza Adriana Fortea Daniel Ilzarbe Gisela Sugranyes Source Type: research
